Accepted Manuscript

Review

Preclinical Models of Nonalcoholic Fatty Liver Disease

Prasanna K. Santhekadur, Divya P. Kumar, Arun J. Sanyal


PII: S0168-8278(17)32422-4

DOI: https://doi.org/10.1016/j.jhep.2017.10.031

Reference: JHEPAT 6741

To appear in: Journal of Hepatology

Received Date: 19 October 2017 Revised Date: 29 October 2017 Accepted Date: 31 October 2017



Please cite this article as: Santhekadur, P.K., Kumar, D.P., Sanyal, A.J., Preclinical Models of Nonalcoholic Fatty Liver Disease, *Journal of Hepatology* (2017), doi: https://doi.org/10.1016/j.jhep.2017.10.031

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

PRECLINICAL MODELS OF NONALCOHOLIC FATTY LIVER DISEASE

Prasanna K. Santhekadur PhD, Divya P. Kumar PhD and Arun J. Sanyal M.B.B.S, M.D.

Running title: animal models of NAFLD

Keywords: nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, fibrosis, NAFLD activity score, transcriptome, mouse models, preclinical models

Corresponding author: Arun J. Sanyal M.D.

Title: Professor of Medicine, Physiology and Molecular

Pathology

Address: MCV Box 980341

Richmond, VA 23298-0341

Phone: (804) 828 6314 Fax: (804) 828 2992

Email: <u>arun.sanyal@vcuhealth.org</u>

Affiliation:

1. Div. of Gastroenterology, Hepatology and Nutrition, Dept. of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA.

Grant support:

- RO1 DK 105961
- T32 DK 07150

Conflicts of Interest:

P.K. Santhekadur: None to report
D.P. Kumar: None to report
A.J. Sanyal: None for this pro-

None for this project. Dr. Sanyal is President of Sanyal Biotechnology and has stock options in Genfit, Akarna, Tiziana, Indalo, Durect. He has served as a consultant to AbbVie, Astra Zeneca, Nitto Denko, Ardelyx, Conatus, Nimbus, Amarin, Salix, Tobira, Takeda, Fibrogen, Jannsen, Gilead, Boehringer, Lilly, Zafgen, Novartis, Pfizer, Immuron, Exhalenz and Genfit. He has been an unpaid consultant to Intercept, Echosens, Immuron, Galectin, Fractyl, Syntlogic, Novo Nordisk, Affimune, Chemomab, Nordic Bioscience and Bristol Myers Squibb. His institution has received grant support from Gilead, Salix, Tobira, Bristol Myers, Shire, Intercept, Merck, Astra Zeneca, Malinckrodt, Cumberland and Novartis. He receives royalties from Elsevier and UptoDate.

Download English Version:

https://daneshyari.com/en/article/8729342

Download Persian Version:

https://daneshyari.com/article/8729342

<u>Daneshyari.com</u>